RVMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Revolution Medicines's net margin of 12.06%. Revolution Medicines's return on equity of -- beat Electromed's return on equity of 16.57%.

Revolution Medicines has a consensus price target of $72.91, signalling upside risk potential of 97.64%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 74.31%. Given that Revolution Medicines has higher upside potential than Electromed, analysts believe Revolution Medicines is more attractive than Electromed.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Revolution Medicines's net income of -$213.4M is lower than Electromed's net income of $1.9M. Notably, Revolution Medicines's price-to-earnings ratio is -- while Electromed's PE ratio is 27.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 3.18x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of -- compared to Revolution Medicines's net margin of -732.34%. Revolution Medicines's return on equity of -- beat Semler Scientific's return on equity of -23.56%.

Revolution Medicines has a consensus price target of $72.91, signalling upside risk potential of 97.64%. On the other hand Semler Scientific has an analysts' consensus of $71.00 which suggests that it could grow by 100.45%. Given that Semler Scientific has higher upside potential than Revolution Medicines, analysts believe Semler Scientific is more attractive than Revolution Medicines.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison Semler Scientific has a beta of 1.392, suggesting its more volatile than the S&P 500 by 39.164%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than Semler Scientific quarterly revenues of $8.8M. Revolution Medicines's net income of -$213.4M is lower than Semler Scientific's net income of -$64.7M. Notably, Revolution Medicines's price-to-earnings ratio is -- while Semler Scientific's PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 6.07x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Revolution Medicines's net margin of -2201.34%. Revolution Medicines's return on equity of -- beat VolitionRX's return on equity of --.

Revolution Medicines has a consensus price target of $72.91, signalling upside risk potential of 97.64%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 282.86%. Given that VolitionRX has higher upside potential than Revolution Medicines, analysts believe VolitionRX is more attractive than Revolution Medicines.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Revolution Medicines's net income of -$213.4M is lower than VolitionRX's net income of -$5.4M. Notably, Revolution Medicines's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 52.93x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Revolution Medicines's net margin of 0.18%. Revolution Medicines's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Revolution Medicines has a consensus price target of $72.91, signalling upside risk potential of 97.64%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 144.76%. Given that Xtant Medical Holdings has higher upside potential than Revolution Medicines, analysts believe Xtant Medical Holdings is more attractive than Revolution Medicines.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Revolution Medicines's net income of -$213.4M is lower than Xtant Medical Holdings's net income of $58K. Notably, Revolution Medicines's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 0.80x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.